Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hBMMSC Injection in Autoimmune Pulmonary Alveolar Proteinosis
NCT07890649Phase 2Not yet recruiting
- Sponsor
- Jiuzhitang Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Oct 2029
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune pulmonary alveolar proteinosis (aPAP) (2 arms), sponsored by Jiuzhitang Co., Ltd. Primary endpoint: Alveolar-arterial difference in oxygen tension at 48 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on NCT07890649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890649.